HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 7 (July)

1. Mode of delivery and postpartum morbidity in Latin American and Caribbean countries among women who are infected with human immunodeficiency virus-1: the NICHD International Site Development Initiative (NISDI) Perinatal Study.
   Am J Obstet Gynecol, 195(1): 215-29. [Abstract] [Full-text]
2. A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication.
   Mol Ther, 14(2): 268-75. [Abstract] [Full-text]
3. HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry.
   Mol Ther, 14(2): 218-25. [Abstract] [Full-text]
4. Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells.
   Mol Ther, 14(2): 236-44. [Abstract] [Full-text]
5. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.
   Mol Ther, 14(2): 276-84. [Abstract] [Full-text]
6. Risk of HIV-1 transmission by breastfeeding among mothers infected with recombinant and non-recombinant HIV-1 genotypes.
   Virus Res, 120(1): 191-8. [Abstract] [Full-text]
7. CD4/CXCR4 co-expression allows productive HIV-1 infection in canine kidney MDCK cells.
   Virus Res, 120(1): 138-45. [Abstract] [Full-text]
8. The migratory experiences of people with HIV/AIDS (PWHA) in Wilmington, North Carolina.
   Health Place, 12(4): 570-9. [Abstract] [Full-text]
9. Use of human immunodeficiency virus postexposure prophylaxis in adolescent sexual assault victims.
   Arch Pediatr Adolesc Med, 160(7): 674-80. [Abstract] [Full-text]
10. Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV.
    Pediatrics, 118(1): 146-55. [Abstract] [Full-text]
11. National estimates of hospital use by children with HIV infection in the United States: analysis of data from the 2000 KIDS Inpatient Database.
    Pediatrics, 118(1): e167-73. [Abstract] [Full-text]
12. Development and evaluation of a qualitative reverse-transcriptase nested polymerase chain reaction protocol for same-day viral validation of human immunodeficiency virus type 1 ribonucleic acid in processed semen.
    Fertil Steril, 86(1): 121-8. [Abstract] [Full-text]
13. Action (verb) fluency predicts dependence in instrumental activities of daily living in persons infected with HIV-1.
    J Clin Exp Neuropsychol, 28(6): 1030-42. [Abstract] [Full-text]
14. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up.
    Blood, 108(2): 460-4. [Abstract] [Full-text]
15. In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase.
    J Biol Chem, 281(28): 19449-56. [Abstract] [Full-text]
16. The HIV-1 pathogenicity factor Nef interferes with maturation of stimulatory T-lymphocyte contacts by modulation of N-Wasp activity.
    J Biol Chem, 281(28): 19618-30. [Abstract] [Full-text]
17. Excellent outcomes of cardiac surgery in patients infected with HIV in the current era.
    Clin Infect Dis, 43(4): 532-6. [Abstract] [Full-text]
18. Gender differences in illicit substance use among middle-aged drug users with or at risk for HIV infection.
    Clin Infect Dis, 43(4): 525-31. [Abstract] [Full-text]
19. HIV vaccines: new frontiers in vaccine development.
    Clin Infect Dis, 43(4): 500-11. [Abstract] [Full-text]
20. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia.
    J Acquir Immune Defic Syndr, 42(4): 412-9. [Abstract] [Full-text]
21. HIV seroincidence estimates among at-risk populations in Buenos Aires and Montevideo: use of the serologic testing algorithm for recent HIV seroconversion.
    J Acquir Immune Defic Syndr, 42(4): 494-500. [Abstract] [Full-text]
22. Children born to HIV-1-infected women in Sweden in 1982-2003: trends in epidemiology and vertical transmission.
    J Acquir Immune Defic Syndr, 42(4): 484-9. [Abstract] [Full-text]
23. Predictors for lower quality of life in the HAART era among HIV-infected men.
    J Acquir Immune Defic Syndr, 42(4): 470-7. [Abstract] [Full-text]
24. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment.
    J Acquir Immune Defic Syndr, 42(4): 464-9. [Abstract] [Full-text]
25. Range of normal neutrophil counts in healthy zimbabwean infants: implications for monitoring antiretroviral drug toxicity.
    J Acquir Immune Defic Syndr, 42(4): 460-3. [Abstract] [Full-text]
26. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers.
    J Acquir Immune Defic Syndr, 42(4): 455-9. [Abstract] [Full-text]
27. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals.
    J Acquir Immune Defic Syndr, 42(4): 435-40. [Abstract] [Full-text]
28. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.
    J Acquir Immune Defic Syndr, 42(4): 426-34. [Abstract] [Full-text]
29. Human herpesvirus 8 oral shedding in HIV-infected men with and without Kaposi sarcoma.
    J Acquir Immune Defic Syndr, 42(4): 420-5. [Abstract] [Full-text]
30. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study.
    J Acquir Immune Defic Syndr, 42(4): 450-4. [Abstract] [Full-text]
31. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.
    J Acquir Immune Defic Syndr, 42(4): 441-9. [Abstract] [Full-text]
32. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients.
    J Acquir Immune Defic Syndr, 42(4): 506-10. [Abstract] [Full-text]
33. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance.
    J Acquir Immune Defic Syndr, 42(4): 501-5. [Abstract] [Full-text]
34. Analysis of polymorphism in the protease and reverse transcriptase genes of HIV type 1 CRF02-AG subtypes from drug-naive patients from Saint-Etienne, France.
    J Acquir Immune Defic Syndr, 42(4): 396-404. [Abstract] [Full-text]
35. Risk reduction counseling is associated with decreased HIV transmission-associated behaviors in high-risk Indian heterosexuals.
    J Acquir Immune Defic Syndr, 42(4): 478-83. [Abstract] [Full-text]
36. Neurodevelopmental outcomes in children with HIV infection under 3 years of age.
    Dev Med Child Neurol, 48(8): 677-82. [Abstract] [Full-text]
37. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells.
    PLoS Pathog, 2(7): e68. [Abstract] [Full-text]
38. DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes.
    PLoS Pathog, 2(7): e70. [Abstract] [Full-text]
39. Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells.
    J Virol, 80(15): 7769-74. [Abstract] [Full-text]
40. Integration of human immunodeficiency virus type 1 in untreated infection occurs preferentially within genes.
    J Virol, 80(15): 7765-8. [Abstract] [Full-text]
41. Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines.
    J Virol, 80(15): 7688-98. [Abstract] [Full-text]
42. Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration.
    J Virol, 80(15): 7658-66. [Abstract] [Full-text]
43. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.
    J Virol, 80(15): 7645-57. [Abstract] [Full-text]
44. Ancient origin and molecular features of the novel human T-lymphotropic virus type 3 revealed by complete genome analysis.
    J Virol, 80(15): 7427-38. [Abstract] [Full-text]
45. Genomic sites of human immunodeficiency virus type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in vivo.
    J Virol, 80(15): 7316-21. [Abstract] [Full-text]
46. Timed Gait test: normative data for the assessment of the AIDS dementia complex.
    J Clin Exp Neuropsychol, 28(7): 1053-64. [Abstract] [Full-text]
47. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York.
    J Infect Dis, 194(4): 428-34. [Abstract] [Full-text]
48. Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men.
    J Infect Dis, 194(4): 420-7. [Abstract] [Full-text]
49. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype.
    J Infect Dis, 194(4): 410-9. [Abstract] [Full-text]
50. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.
    J Clin Oncol, 24(21): 3408-14. [Abstract] [Full-text]
51. Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
    JAMA, 296(3): 292-300. [Abstract] [Full-text]
52. Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies.
    Med Care, 44(8): S52-60. [Abstract] [Full-text]
53. Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans.
    Med Care, 44(8): S44-51. [Abstract] [Full-text]
54. Associations between alcohol use and homelessness with healthcare utilization among human immunodeficiency virus-infected veterans.
    Med Care, 44(8): S37-43. [Abstract] [Full-text]
55. Intoxication before intercourse and risky sexual behavior in male veterans with and without human immunodeficiency virus infection.
    Med Care, 44(8): S31-6. [Abstract] [Full-text]
56. Adolescent adjustment over six years in HIV-affected families.
    J Adolesc Health, 39(2): 174-82. [Abstract] [Full-text]
57. Associations among body composition, androgen levels, and human immunodeficiency virus status in adolescents.
    J Adolesc Health, 39(2): 164-73. [Abstract] [Full-text]
58. Epidemiology of HIV and AIDS among adolescents and young adults in the United States.
    J Adolesc Health, 39(2): 156-63. [Abstract] [Full-text]
59. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
    Lancet, 368(9532): 287-98. [Abstract] [Full-text]
60. HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death.
    J Med Virol, 78(9): 1141-6. [Abstract] [Full-text]
61. Interleukin-2 reconstitutes defective human immunodeficiency virus (HIV), and cytomegalovirus (CMV) specific CD8+ T cell proliferation in HIV infection.
    J Med Virol, 78(9): 1147-57. [Abstract] [Full-text]
62. Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.
    J Med Virol, 78(9): 1158-63. [Abstract] [Full-text]
63. Diffusion of the D.A.R.E and syringe exchange programs.
    Am J Public Health, 96(8): 1354-8. [Abstract] [Full-text]
64. Orphan care in Botswana's working households: growing responsibilities in the absence of adequate support.
    Am J Public Health, 96(8): 1429-35. [Abstract] [Full-text]
65. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.
    Neurology, 67(2): 311-4. [Abstract] [Full-text]
66. Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function.
    Clin Immunol, 120(2): 163-70. [Abstract] [Full-text]
67. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals.
    Clin Immunol, 120(2): 138-46. [Abstract] [Full-text]
68. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier.
    J Cereb Blood Flow Metab, 26(8): 1052-65. [Abstract] [Full-text]
69. Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial.
    J Acquir Immune Defic Syndr, 42(5): 637-45. [Abstract] [Full-text]
70. Risk factors for HIV infection in a national adult population: evidence from the 2003 Kenya Demographic and Health Survey.
    J Acquir Immune Defic Syndr, 42(5): 627-36. [Abstract] [Full-text]
71. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection.
    J Acquir Immune Defic Syndr, 42(5): 620-6. [Abstract] [Full-text]
72. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.
    J Acquir Immune Defic Syndr, 42(5): 614-9. [Abstract] [Full-text]
73. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
    J Acquir Immune Defic Syndr, 42(5): 554-61. [Abstract] [Full-text]
74. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial.
    J Acquir Immune Defic Syndr, 42(5): 523-8. [Abstract] [Full-text]
75. A tryptophan-rich hexapeptide inhibits nucleic acid destabilization chaperoned by the HIV-1 nucleocapsid protein.
    Biochemistry, 45(30): 9254-65. [Abstract] [Full-text]
76. Fat distribution in women with HIV infection.
    J Acquir Immune Defic Syndr, 42(5): 562-71. [Abstract] [Full-text]
77. Containing HIV/AIDS in India: the unfinished agenda.
    Lancet Infect Dis, 6(8): 508-21. [Abstract] [Full-text]
78. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.
    Lancet Infect Dis, 6(8): 496-507. [Abstract] [Full-text]
79. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration.
    Lancet Infect Dis, 6(8): 483-95. [Abstract] [Full-text]
80. Incidence of tuberculin skin test conversion among HIV-infected and -uninfected women: results of a 6-year study.
    J Acquir Immune Defic Syndr, 42(5): 592-6. [Abstract] [Full-text]
81. The use of an educational video during informed consent in an HIV clinical trial in Haiti.
    J Acquir Immune Defic Syndr, 42(5): 588-91. [Abstract] [Full-text]
82. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months.
    J Acquir Immune Defic Syndr, 42(5): 584-7. [Abstract] [Full-text]
83. Assessment of the association between HIV viral load and CD4 cell count on the occurrence of oropharyngeal candidiasis in HIV-infected patients.
    J Acquir Immune Defic Syndr, 42(5): 578-83. [Abstract] [Full-text]
84. Progressive prothrombotic state in women with advancing HIV disease.
    J Acquir Immune Defic Syndr, 42(5): 572-7. [Abstract] [Full-text]
85. In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers.
    J Acquir Immune Defic Syndr, 42(5): 545-53. [Abstract] [Full-text]
86. Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy.
    J Acquir Immune Defic Syndr, 42(5): 537-44. [Abstract] [Full-text]
87. alpha-Defensins 1, 2, and 3 are expressed by granulocytes in lymphoid tissues of HIV-1-seropositive and -seronegative individuals.
    J Acquir Immune Defic Syndr, 42(5): 529-36. [Abstract] [Full-text]
88. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
    J Acquir Immune Defic Syndr, 42(5): 610-3. [Abstract] [Full-text]
89. Unsafe sex with casual partners and quality of life among HIV-infected gay men: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA).
    J Acquir Immune Defic Syndr, 42(5): 597-603. [Abstract] [Full-text]
90. Origins of HIV and the evolution of resistance to AIDS.
    Science, 313(5786): 462-6. [Abstract] [Full-text]
91. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1.
    Science, 313(5786): 523-6. [Abstract] [Full-text]
92. Current status of antiretroviral therapy.
    Expert Opin Pharmacother, 7(12): 1541-54. [Abstract] [Full-text]
93. Can gene delivery close the door to HIV-1 entry after escape?
    J Med Primatol, 35(4): 236-47. [Abstract] [Full-text]
94. Causes of visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
    Ophthalmology, 113(8): 1441-5. [Abstract] [Full-text]
95. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
    Ophthalmology, 113(8): 1432-40. [Abstract] [Full-text]
96. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy.
    Thorax, 61(8): 716-21. [Abstract] [Full-text]
97. Primary mania versus HIV-related secondary mania in Uganda.
    Am J Psychiatry, 163(8): 1349-54; quiz 1480. [Abstract] [Full-text]
98. Contrast sensitivity and color vision in HIV-infected individuals without infectious retinopathy.
    Am J Ophthalmol, 142(2): 284-92. [Abstract] [Full-text]
99. HIV surveillance in theory and practice: assessing the acceptability of California's non-name HIV surveillance regulations.
    Health Policy, 78(1): 101-10. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.